+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, and Segment Forecasts, 2021-2028

  • ID: 5457652
  • Report
  • October 2021
  • Region: Global
  • 100 Pages
  • Grand View Research

FEATURED COMPANIES

  • Aurora healthcare
  • Biogen
  • Covance
  • GlaxoSmithKline
  • Icon Plc
  • IQVIA
The global neurology clinical trials market size is expected to reach USD 7.4 billion by 2028. The market is expected to expand at a CAGR of 5.5% from 2021 to 2028. This is largely attributed to big pharma companies conducting innovative trials in neurology, increased government funding from the National Institute of Neurological Disorders and Stroke (NINDS), and stringent regulatory requirements pertaining to clinical trials.





Neuroscience continues to receive a healthy level of early investment. It received USD 1.5 billion in venture capital funding in 2018, second only to cancer, indicating that investors expect a large pharma acquisition to pay off in the near future. As the industry strives to move past the many late-stage clinical failures of recent years, early diagnosis of diseases is attracting investment and driving deal-making in the complex neuroscience sector, particularly for pain and Alzheimer's disease.

In terms of deal volume, no other therapy area comes close to matching oncology, but neuroscience is among the nearest contenders. Despite a drop in total expected value in 2017, the number of neuroscience-related licensing deals has gradually climbed over the last decade. The vast majority of neuroscience agreements ~90%have a primary neurological focus, which corresponds to the level of R&D activity in the two disciplines.

Many experimental therapeutics require dosage by on-site administration and carefully scheduled outcome measure evaluations hence, the COVID-19 pandemic has significantly harmed the implementation of the precise procedures required to establish proof of safety and efficacy. The COVID-19 has resulted in the shutdown of the network of centers conducting stroke clinical trials. This was followed by a phased research restart plan that took local circumstances and regulatory oversight into account. This approach was successful in a reengaging research effort to some extent in all but one of the ongoing investigations within 55 days.

Neurology Clinical Trials Market Report Highlights

  • The phase II segment dominated the market and accounted for a maximum revenue share of 36.7% in 2020. Between 1999 and 2020, 8,205 CNS trials were conducted, with 609 trials being conducted in 2020.
  • The interventional segment held the largest market revenue share of 81.1% in 2020.
  • The Huntington's disease segment is anticipated to register the fastest CAGR of 6.0% over the forecast period. This is largely due to the high prevalence of the disease around the world.
  • North America dominated the market and accounted for a revenue share of 45.8% in 2020. The rising prevalence of neurological disorders and the presence of a large number of players in clinical trials drive the market in the region.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Neurology Clinical Trials Market

What is the estimated value of the Global Neurology Clinical Trials Market?

The Global Neurology Clinical Trials Market was estimated to be valued at $5.1 billion in 2021.

What is the growth rate of the Global Neurology Clinical Trials Market?

The growth rate of the Global Neurology Clinical Trials Market is 5.5%, with an estimated value of $7.4 billion by 2028.

What is the forecasted size of the Global Neurology Clinical Trials Market?

The Global Neurology Clinical Trials Market is estimated to be worth $7.4 billion by 2028.

Who are the key companies in the Global Neurology Clinical Trials Market?

Key companies in the Global Neurology Clinical Trials Market include IQVIA, Novartis, Covance, Medpace, Charles River Laboratories, Icon Plc, GlaxoSmithKline, Aurora healthcare and Biogen.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aurora healthcare
  • Biogen
  • Covance
  • GlaxoSmithKline
  • Icon Plc
  • IQVIA

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Region Wise Market Calculation
1.6.1 Region Wise Market: Base Estimates
1.6.2 Global Market: CAGR Calculation
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective - 1: Understanding market dynamics
1.8.2 Objective - 2: Understanding market estimates and forecasts
1.8.3 Objective - 3: Understanding attributes such as strategy framework and competitor categorization
1.8.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size.
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Neurology Clinical Trials Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing neurological disease, such as dementia, stroke, and peripheral neuropathy
3.2.1.2 Increasing R&D investments
3.2.1.3 Stringent Regulatory Requirements
3.2.2 Market Restraint Analysis
3.2.2.1 High Failure Rates of Trials
3.2.2.2 Rising Cost of Clinical Trials
3.3 Penetration & Growth Prospect Mapping
3.4 COVID-19 Impact on the Market
3.5 Major Deals and Strategic Alliances Analysis
3.6 Neurology Clinical Trials: Market Analysis Tools
3.6.1 Industry Analysis - Porter’s
3.6.3 PESTEL Analysis
Chapter 4 Neurology Clinical Trials Market: Phase Segment Analysis
4.1 Neurology Clinical Trials Market: Phase Market Share Analysis, 2020 & 2028
4.2 Phase I
4.2.1 Phase I Market, 2016 - 2028 (USD Million)
4.3 Phase II
4.3.1 Phase II Market, 2016 - 2028 (USD Million)
4.4 Phase III
4.4.1 Phase III Market, 2016 - 2028 (USD Million)
4.5 Phase IV
4.5.1 Phase IV Market, 2016 - 2028 (USD Million)
Chapter 5 Neurology Clinical Trials Market: Study Design Segment Analysis
5.1 Neurology Clinical Trials Market: Study Design Market Share Analysis, 2020 & 2028
5.2 Interventional
5.2.1 Interventional Market, 2016 - 2028 (USD Million)
5.3 Observational
5.3.1 Observational Market, 2016 - 2028 (USD Million)
5.4 Expanded Access
5.4.1 Expanded Access Market, 2016 - 2028 (USD Million)
Chapter 6 Neurology Clinical Trials Market: Indication Segment Analysis
6.1 Neurology Clinical Trials: Indication Market Share Analysis, 2020 & 2028
6.2 Epilepsy
6.2.1 Epilepsy Market, 2016 - 2028 (USD Million)
6.3 Parkinson's Disease
6.3.1 Parkinson's Disease Market, 2016 - 2028 (USD Million)
6.4 Huntington's Disease
6.4.1 Huntington's Disease Market, 2016 - 2028 (USD Million)
6.5 Stroke
6.5.1 Stroke Market, 2016 - 2028 (USD Million)
6.6 Traumatic Brain Injury
6.6.1 Traumatic Brain Injury Market, 2016 - 2028 (USD Million)
6.7 Amyotrophic Lateral Sclerosis
6.7.1 Amyotrophic Lateral Sclerosis Market, 2016 - 2028 (USD Million)
6.8 Muscle regeneration
6.8.1 Muscle regeneration Market, 2016 - 2028 (USD Million)
6.9 Others
6.9.1 Others Market, 2016 - 2028 (USD Million)
Chapter 7 Neurology Clinical Trials Market: Regional Analysis
7.1 Neurology Clinical Trials Market: Regional Market Share Analysis, 2020 & 2028
7.2 North America
7.2.1 North America Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3 Europe
7.3.1 Europe Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3.2 U.K.
7.3.2.1 U.K. Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3.4 France
7.3.4.1 France Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3.5 Italy
7.3.5.1 Italy Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.3.6 Spain
7.3.6.1 Spain Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4.3 China
7.4.3.1 China Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4.4 India
7.4.4.1 India Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4.5 Australia
7.4.5.1Australia Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.5 Latin America
7.5.1 Latin America Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.5.5 Colombia
7.5.5.1 Colombia Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.6 MEA
7.6.1 MEA Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
7.6.4 UAE
7.6.4.1 UAE Neurology Clinical Trials Market, 2016 - 2028 (USD Million)
Chapter 8 Company Profiles
8.1 IQVIA
8.1.1 Company Overview
8.1.2 Service Benchmarking
8.1.3 Financial Performance
8.1.4 Strategic Initiatives
8.2 Novartis
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Service Benchmarking
8.2.4 Strategic Initiatives
8.3 Covance
8.3.1 Company Overview
8.3.2 Service Benchmarking
8.3.3 Strategic Initiatives
8.4 Medpace
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Service Benchmarking
8.5 Charles River Laboratories
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Service Benchmarking
8.6 Icon Plc
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Service Benchmarking
8.7 GlaxoSmithKline
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Service Benchmarking
8.7.4 Strategic Initiatives
8.8 Aurora healthcare
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Service Benchmarking
8.9 Charles River Laboratories
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Service Benchmarking
8.9.4 Strategic Initiatives
8.10 Biogen
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Service Benchmarking
8.10.4 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Neurology Clinical Trials Market, by region, 2016-2028 (USD Million)
Table 4 Global Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 5 Global Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 6 Global Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 7 North America Neurology Clinical Trials Market, by Country, 2016-2028 (USD Million)
Table 8 North America Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 9 North America Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 10 North America Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 11 U.S. Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 12 U.S. Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 13 U.S. Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 14 Canada Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 15 Canada Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 16 Canada Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 17 Europe Neurology Clinical Trials Market, by Country, 2016-2028 (USD Million)
Table 18 Europe Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 19 Europe Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 20 Europe Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 21 U.K. Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 22 U.K. Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 23 U.K. Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 24 Germany Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 25 Germany Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 26 Germany Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 27 France Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 28 France Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 29 France Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 30 Italy Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 31 Italy Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 32 Italy Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 33 Spain Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 34 Spain Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 35 Spain Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 36 Asia Pacific Neurology Clinical Trials Market, by Country, 2016-2028 (USD Million)
Table 37 Asia Pacific Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 38 Asia Pacific Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 39 Asia Pacific Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 40 India Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 41 India Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 42 India Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 43 Japan Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 44 Japan Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 45 Japan Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 46 China Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 47 China Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 48 China Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 49 Australia Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 50 Australia Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 51 Australia Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 52 South Korea Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 53 South Korea Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 54 South Korea Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 55 Latin America Neurology Clinical Trials Market, by Country, 2016-2028 (USD Million)
Table 56 Latin America Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 57 Latin America Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 58 Latin America Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 59 Brazil Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 60 Brazil Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 61 Brazil Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 62 Mexico Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 63 Mexico Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 64 Mexico Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 65 Argentina Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 66 Argentina Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 67 Argentina Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 68 Colombia Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 69 Colombia Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 70 Colombia Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 71 MEA Neurology Clinical Trials Market, by Country, 2016-2028 (USD Million)
Table 72 MEA Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 73 MEA Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 74 MEA Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 75 South Africa Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 76 South Africa Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 77 South Africa Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 78 South Arabia Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 79 South Arabia Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 80 South Arabia Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
Table 81 UAE Neurology Clinical Trials Market, by Phase, 2016-2028 (USD Million)
Table 82 UAE Neurology Clinical Trials Market, by Study Design, 2016-2028 (USD Million)
Table 83 UAE Neurology Clinical Trials Market, by Indication, 2016-2028 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Secondary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Neurology clinical trials market snapshot (2020)
Fig. 8 Neurology clinical trials market segmentation
Fig. 9 Market driver relevance analysis (Current & future impact)
Fig. 10 Market restraint relevance analysis (Current & future impact)
Fig. 11 Penetration & growth prospect mapping
Fig. 12 Porter’s five forces analysis
Fig. 13 PESTEL analysis
Fig. 14 Neurology clinical trials market phase outlook: Segment dashboard
Fig. 15 Neurology clinical trials market: Phase movement analysis
Fig. 16 Phase I market, 2016-2028 (USD Million)
Fig. 17 Phase II market, 2016-2028 (USD Million)
Fig. 18 Phase III market, 2016-2028 (USD Million)
Fig. 19 Phase IV market, 2016-2028 (USD Million)
Fig. 20 Neurology clinical trials market study design outlook: Segment dashboard
Fig. 21 Neurology clinical trials market: Study Design movement analysis
Fig. 22 Interventional market, 2016-2028 (USD Million)
Fig. 23 Observational market, 2016-2028 (USD Million)
Fig. 24 Expanded access market, 2016-2028 (USD Million)
Fig. 25 Neurology clinical trials market indication outlook: Segment dashboard
Fig. 26 Neurology clinical trials market: Indication movement analysis
Fig. 27 Epilepsy market, 2016-2028 (USD Million)
Fig. 28 Parkinson's disease market, 2016-2028 (USD Million)
Fig. 29 Huntington's disease market, 2016-2028 (USD Million)
Fig. 30 Stroke indication market, 2016-2028 (USD Million)
Fig. 31 Traumatic Brain Injury market, 2016-2028 (USD Million)
Fig. 32 Amyotrophic Lateral Sclerosis market, 2016-2028 (USD Million)
Fig. 33 Muscle regeneration market, 2016-2028 (USD Million)
Fig. 34 Others indication market, 2016-2028 (USD Million)
Fig. 35 Regional market: Key takeaways
Fig. 36 Regional outlook, 2020 & 2028
Fig. 37 North America market, 2016-2028 (USD Million)
Fig. 38 U.S. market, 2016-2028 (USD Million)
Fig. 39 Canada market, 2016-2028 (USD Million)
Fig. 40 Europe market, 2016-2028 (USD Million)
Fig. 41 U.K. market, 2016-2028 (USD Million)
Fig. 42 Germany market, 2016-2028 (USD Million)
Fig. 43 France market, 2016-2028 (USD Million)
Fig. 44 Italy market, 2016-2028 (USD Million)
Fig. 45 Spain market, 2016-2028 (USD Million)
Fig. 46 Asia Pacific market, 2016-2028 (USD Million)
Fig. 47 Japan market, 2016-2028 (USD Million)
Fig. 48 China market, 2016-2028 (USD Million)
Fig. 49 India market, 2016-2028 (USD Million)
Fig. 50 Australia market, 2016-2028 (USD Million)
Fig. 51 South Korea market, 2016-2028 (USD Million)
Fig. 52 Latin America market, 2016-2028 (USD Million)
Fig. 53 Brazil market, 2016-2028 (USD Million)
Fig. 54 Mexico market, 2016-2028 (USD Million)
Fig. 55 Argentina market, 2016-2028 (USD Million)
Fig. 56 Colombia market, 2016-2028 (USD Million)
Fig. 57 MEA market, 2016-2028 (USD Million)
Fig. 58 South Africa market, 2016-2028 (USD Million
Fig. 59 Saudi Arabia market, 2016-2028 (USD Million)
Fig. 60 UAE market, 2016-2028 (USD Million)
Note: Product cover images may vary from those shown
  • IQVIA
  • Novartis
  • Covance
  • Medpace
  • Charles River Laboratories
  • Icon Plc
  • GlaxoSmithKline
  • Aurora healthcare
  • Charles River Laboratories
  • Biogen
Note: Product cover images may vary from those shown

Loading
LOADING...

RELATED TAGS

RELATED PRODUCTS

In Silico Clinical Trials Market Size, Share & Trends Analysis Report by Therapeutic Area (Oncology, Infectious Diseases), by Phase (Phase I, II, III), by Industry (Medical Devices, Pharmaceutical), and Segment Forecasts, 2022-2030 - Product Image

In Silico Clinical Trials Market Size, Share & Trends Analysis Report by Therapeutic Area (Oncology, Infectious Diseases), by Phase (Phase I, II, III), by Industry (Medical Devices, Pharmaceutical), and Segment Forecasts, 2022-2030

  • Report
  • 180 Pages
  • Region: Global
Global Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials), by Indication, by Region, and Segment Forecasts, 2021-2028 - Product Image

Global Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials), by Indication, by Region, and Segment Forecasts, 2021-2028

  • Report
  • 100 Pages
  • Region: Global
Clinical Trial Imaging Market Research Report by Product & Service (Services and Software), Modality, Therapeutic area, End-User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19 - Product Image

Clinical Trial Imaging Market Research Report by Product & Service (Services and Software), Modality, Therapeutic area, End-User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • Report
  • 198 Pages
  • Region: Global
Clinical Trial Imaging Market by Software & Services (Operational Imaging, Read Analysis), Modality (CT, MRI, X-Ray, PET, Ultrasound, ECHO), Therapeutic Areas (Infectious, Oncology, CNS, CVS), End User (Pharma, Biotechnology, CRO) - Global Forecast to 2026 - Product Image

Clinical Trial Imaging Market by Software & Services (Operational Imaging, Read Analysis), Modality (CT, MRI, X-Ray, PET, Ultrasound, ECHO), Therapeutic Areas (Infectious, Oncology, CNS, CVS), End User (Pharma, Biotechnology, CRO) - Global Forecast to 2026

  • Report
  • 199 Pages
  • Region: Global
Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) - Global Forecast to 2026 - Product Image

Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) - Global Forecast to 2026

  • Report
  • 306 Pages
  • Region: Global
Copyright © 2002-2022 Research and Markets. All Rights Reserved.